OA-425 - Phase 1b trial of the full-length MSP1/GLA-SE malaria vaccine SUM-101 in healthy, malaria-exposed adults in Tanzania
Speakers:
- Aina-ekisha Kahatano, Ifakara Health Institute, Kenya
OA-703 - First ever use of a Controlled Human Malaria Infection-Transmission (CHMI-trans) model to assess the efficacy of a transmission-blocking vaccine: Plasmodium falciparum ProC6C-AlOH/Matrix-M vaccine in adults
Speakers:
- Adama Sacko, Malaria Research and Training Center (MRTC), Mali
OA-144 - A phase III randomized controlled multi-centre trial evaluating the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
Speakers:
- Angela Gwakisa, Ifakara Health Institute, Tanzania
OA-689 - Seasonal R21 mass vaccination for malaria elimination
Speakers:
- Edgard Dabira, MRC Unit The Gambia at The London School of Hygiene and Tropical Medicine, The Gambia
OA-339 - Design of a case-control study to monitor effectiveness of the RTS,S/AS01 malaria vaccine against severe malaria, and association with safety signals
Speakers:
- Thomas Gyan, Kintampo Health Research Centre, Research and Development Division, Ghana Health Service, Ghana